BRIEF published on 09/18/2024 at 07:05, 2 years ago Relief Therapeutics achève la phase clinique de l'étude RLF-OD032 Étude Clinique RLF-OD032 Biodisponibilité Phénylcétonurie Dichlorhydrate De Saproptérine
BRIEF published on 09/18/2024 at 07:05, 2 years ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 2 years ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 2 years 1 month ago Relief Therapeutics annonce la présentation des résultats de l'étude PKU GOLIKE au SSIEM 2024 Essai Clinique PKU GOLIKE THÉRAPEUTIQUE DE SECOURS SSIEM 2024 Phénylcétonurie
BRIEF published on 09/02/2024 at 07:05, 2 years 1 month ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 2 years 1 month ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 2 years 1 month ago Relief Therapeutics publie ses résultats financiers du premier semestre 2024 et une mise à jour de l'entreprise Résultats Financiers Essais Cliniques Mise À Jour De L'entreprise Augmentation Des Revenus Réserves De Trésorerie
BRIEF published on 08/30/2024 at 07:05, 2 years 1 month ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 2 years 1 month ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 2 years 2 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
Published on 10/06/2026 at 16:30, 12 minutes ago Snipp Survey Finds AI is Reshaping the Shopper Journey, with 61.8% of AI Users Having Purchased After an AI Recommendation
Published on 10/06/2026 at 15:45, 57 minutes ago Stagwell Launches New Global Media Agency, Stagwell Media
Published on 10/06/2026 at 15:00, 1 hour 42 minutes ago Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Published on 10/06/2026 at 14:31, 2 hours 11 minutes ago Worksport (Nasdaq: WKSP) Books $2.92M August Orders; Annualized Order Run Rate Reaches $35M
Published on 10/06/2026 at 13:30, 3 hours 12 minutes ago Golden Minerals Commences Drilling at its Desierto Property, Argentina
Published on 10/06/2026 at 16:35, 7 minutes ago Viola Aleo Ltd: First in Financial Intermediation for Five Consecutive Years
Published on 10/06/2026 at 16:30, 12 minutes ago Original-Research: Evonik Industries AG (von Parmantier & Cie. GmbH): Hold
Published on 10/06/2026 at 16:30, 12 minutes ago Original-Research: LANXESS AG (von Parmantier & Cie. GmbH): Buy
Published on 10/06/2026 at 16:15, 27 minutes ago Eleving Group announces early voluntary redemption of its EUR 90,000,000 13% Senior Secured Bonds 2023/2028 (ISIN: DE000A3LL7M4)
Published on 10/06/2026 at 16:05, 37 minutes ago Rockwell Automation Expands SecureOT Managed Services to Support Fortinet Firewalls and Existing Customer Infrastructure
Published on 10/05/2026 at 22:12, 18 hours 30 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 18 hours 30 minutes ago AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 22 hours 29 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 22 hours 29 minutes ago Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 22 hours 42 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
